• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Dexcom Receives FDA Clearance for G7 Continuous Glucose Monitoring (CGM) System

Share:

December 12, 2022

What You Should Know:

The FDA has cleared Dexcom G7 continuous glucose monitoring (CGM) system in the U.S. for people with all types of diabetes ages two years and older, giving more people than ever access to a powerfully simple diabetes management solution.

Cleared as an integrated continuous glucose monitoring (iCGM) system, Dexcom G7 will be part of the most connected CGM ecosystem in the world,1 with real-time connectivity that can drive integrated insulin delivery systems, connect with wearables like the Apple Watch and integrate with popular digital health apps.

With an overall MARD of 8.2%, Dexcom G7 is the most accurate CGM cleared by the FDA, building on the trusted performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia and increase time in range.
Source: HIT Consultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Thirty Madison Reaches $1B Valuation with $140M Series C FundingThirty Madison Reaches $1B Valuation with $140M Series C Funding
  • Cleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc.Cleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc.
  • Underwriters Laboratories acquires British human factors firm Medical Device UsabilityUnderwriters Laboratories acquires British human factors firm Medical Device Usability
  • A!maginostic Partners A*star’s Institute of Molecular and Cell Biology to Establish a New Joint Lab of Excellence for Smart Digital and Multiplex PathologyA!maginostic Partners A*star’s Institute of Molecular and Cell Biology to Establish a New Joint Lab of Excellence for Smart Digital and Multiplex Pathology
  • Deepening its Immune-Related Disease Pipeline, Alexion Buys Achillion for $930 MillionDeepening its Immune-Related Disease Pipeline, Alexion Buys Achillion for $930 Million
  • Sientra Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Sientra Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • Cosette Pharmaceuticals Announces the Acquisition of G&W Laboratories’ Lincolnton, NC Finished Dosage Manufacturing PlantCosette Pharmaceuticals Announces the Acquisition of G&W Laboratories’ Lincolnton, NC Finished Dosage Manufacturing Plant
  • Kindeva Drug Delivery Acquires Summit Biosciences, a Specialized Nasal Drug Development and Manufacturing OrganizationKindeva Drug Delivery Acquires Summit Biosciences, a Specialized Nasal Drug Development and Manufacturing Organization

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications